methylprednisolone + isavuconazole

Methylprednisolone + isavuconazole refers to an experimental treatment strategy being evaluated in the EFRAIM II clinical trial (NCT04680884), sponsored by Assistance Publique - Hôpitaux de Paris. This protocol involves the empirical administration of methylprednisolone, a synthetic glucocorticoid, and isavuconazole, a triazole antifungal, to immunocompromised patients (such as those with hematological malignancies or solid organ transplants) who present with acute respiratory failure of undetermined etiology. Methylprednisolone acts as an anti-inflammatory agent by binding to and activating the glucocorticoid receptor, while isavuconazole inhibits the enzyme lanosterol 14-alpha-demethylase, thereby disrupting fungal ergosterol synthesis and cell membrane integrity. The strategy aims to improve survival by providing early, empirical coverage for potential steroid-responsive conditions (e.g., organized pneumonia) and occult invasive fungal infections.

Other names

EFRAIM 2EFRAIM2EFRAIM-2experimental-Assistance Publique - Hôpitaux de Paris-acute respiratory failure